Emerging novel and antimicrobial-resistant respiratory tract infections: New drug development and therapeutic options

The Lancet Infectious Diseases

Volumn 14, Issue 11, 2014, Pages 1136-1149

  Zumla, Alimuddin ^a,b,c,d   Memish, Ziad A ^d,e   Maeurer, Markus ^f   Bates, Matthew ^a,c   Mwaba, Peter ^c   Al Tawfiq, Jaffar A ^g,h   Denning, David W ⁱ   Hayden, Frederick G ^j   Hui, David S ^k  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c UNIVERSITY OF ZAMBIA   (Zambia)

^d MINISTRY OF HEALTH   (Saudi Arabia)

^e ALFAISAL UNIVERSITY   (Saudi Arabia)

^f KAROLINSKA INSTITUTE   (Sweden)

^g DHAHRAN HEALTH CENTER   (Saudi Arabia)

^h INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^j UNIVERSITY OF VIRGINIA   (United States)

^k CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

more..

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; ADAMANTANE; ALPHA2B INTERFERON; AMANTADINE; AMPHOTERICIN B; ANTIINFECTIVE AGENT; BEDAQUILINE; DELAMANID; ECHINOCANDIN; ENOXACIN; FAVIPIRAVIR; FLUCONAZOLE; GALACTOMANNAN; ISAVUCONAZOLE; ITRACONAZOLE; LANINAMIVIR; NITAZOXANIDE; OSELTAMIVIR; PERAMIVIR; RAPAMYCIN; RIBAVIRIN; RIMANTADINE; VORICONAZOLE; ZANAMIVIR; ANTIFUNGAL AGENT; ANTIVIRUS AGENT;

2009 H1N1 INFLUENZA; AVIAN INFLUENZA A H10N8; BIOLOGICAL THERAPY; CELL THERAPY; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; INCIDENCE; INFLUENZA A (H1N1); INFLUENZA A (H5N1); INFLUENZA A H7N9; INFLUENZA B; INFLUENZA C; LUNG ASPERGILLOSIS; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS INFECTION; MONOTHERAPY; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; RESPIRATORY TRACT INFECTION; REVIEW; SEVERE ACUTE RESPIRATORY SYNDROME; SPECIFIC ANTIBODY THERAPY; T LYMPHOCYTE; VIRUS INFECTION; ANTIBIOTIC RESISTANCE; ANTIFUNGAL RESISTANCE; ANTIVIRAL RESISTANCE; BACTERIAL INFECTIONS; DRUG DEVELOPMENT; MICROBIOLOGY; MYCOSES; PROCEDURES; RESPIRATORY TRACT INFECTIONS; TREATMENT OUTCOME; TRENDS; VIROLOGY; VIRUS DISEASES;

ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; ANTIVIRAL AGENTS; BACTERIAL INFECTIONS; BIOLOGICAL THERAPY; DRUG DISCOVERY; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, FUNGAL; DRUG RESISTANCE, VIRAL; DRUG THERAPY; HUMANS; MYCOSES; RESPIRATORY TRACT INFECTIONS; TREATMENT OUTCOME; VIRUS DISEASES;

EID: 84908278915     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(14)70828-X     Document Type: Review

References (165)

1. Al-Tawfiq JA, Zumla A, Gautret P, et al. Surveillance for emerging respiratory viruses. Lancet Infect Dis 2014, published online Sept 2. http://dx.doi.org/10.1016/S1473-3099(14)70840-0.
2. Zumla A, Abubakar I, Raviglione M, et al. Drug-resistant tuberculosis-current dilemmas, unanswered questions, challenges, and priority needs. J Infect Dis 2012, 205(suppl 2):S228-S240.
3. Magiorakos AP, Suetens C, Monnet DL, et al. The rise of carbapenem resistance in Europe: just the tip of the iceberg?. Antimicrob Resist Infect Control 2013, 2:6.
4. Van der Linden JW, Camps SM, Kampinga GA, et al. Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles. Clin Infect Dis 2013, 57:513-520.
5. Chan JF, To KK, Tse H, Jin DY, Yuen KY Interspecies transmission and emergence of novel viruses: lessons from bats and birds. Trend Microb 2013, 21:544-555.
6. Yuen KY, Chan PK, Peiris M, et al. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet 1998, 351:467-471.
7. Zhu H, Webby R, Lam TT, Smith DK, Peiris JS, Guan Y History of swine influenza viruses in Asia. Curr Topic Microb Immun 2013, 370:57-68.
8. Barr IG WHO recommendations for the viruses used in the 2013-2014 northern hemisphere influenza vaccine: epidemiology, antigenic and genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B influenza viruses collected from October 2012 to January 2013. Vaccine 2014, 32:4713-4725. Writing Committee of the World Health Organization Consultation on Northern Hemisphere Influenza Vaccine Composition for 2013-2014.
9. Avian influenza A(H7N9) virus WHO, (accessed Feb 14, 2014). http://www.who.int/influenza/human_animal_interface/influenza_h7n9/en/.
10. Chen H, Yuan H, Gao R, et al. Clinical and epidemiological characteristics of a fatal case of avian influenza A H10N8 virus infection: a descriptive study. Lancet 2014, 383:714-721.
11. Legand AL, Briand S, Shindo N, et al. Addressing the public health burden of respiratory viruses: the battle against respiratory viruses (BRaVe) Initiative. Future Virol 2013, 8:953-968.
12. Ison MG, Gnann JW, Nagy-Agren S, et al. Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir Ther 2003, 8:183-190. for the NIAID Collaborative Antiviral Study Group.
13. Antiviral agents for the treatment and chemoprophylaxis of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morbid Mortal Weekly Rep 2011, 60:1-24. US Centers for Disease Control and Prevention.
14. Govorkova EA, Baranovich T, Seiler P, Armstrong J, Burnham A, Guan Y Antiviral resistance among highly pathogenic influenza A (H5N1) viruses isolated worldwide in 2002-2012 shows need for continued monitoring. Antiviral Res 2013, 98:297-304.
15. Hayden FG Newer influenza antivirals, biotherapeutics and combinations. Influenza Other Resp Virus 2012, 7(suppl 1):63-75.
16. Lee N, Chan PK, Lui GC, et al. Complications and outcomes of pandemic 2009 influenza A (H1N1) virus infection in hospitalized adults: how do they differ from those in seasonal influenza?. J Infect Dis 2011, 203:1739-1747.
17. Muthuri SG, Venkatesan S, Myles PR, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med 2014, 2:395-404.
18. Chan PK, Lee N, Saman M, et al. Determinants of antiviral effectiveness in influenza virus A subtype H5N1. J Infect Dis 2012, 206:1359-1366.
19. Adisasmito W, Chan PK, Lee N, et al. Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a global patient registry. J Infect Dis 2010, 202:1154-1160.
20. Hu Y, Lu S, Song Z, et al. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet 2013, 381:2273-2279.
21. Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial. BMJ 2013, 346:f3039. South East Asia Infectious Disease Clinical Research Network.
22. Lee N, Hui DS, Zuo Z, et al. A prospective intervention study on higher-dose oseltamivir treatment in adults hospitalized with influenza A and B infections. Clin Infect Dis 2013, 57:1511-1519.
23. Kumar A, the ROSII Study Investigators. Viral clearance with standard or triple dose oseltamivir therapy in critically ill patients with pandemic (H1N1) 2009 influenza. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy; Denver, CO, USA; Sept 10-13, 2013. Abstr V-1470.
24. Kohno S, Kida H, Mizuguchi M, et al. Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients. Antimicrob Agents Chemother 2011, 55:2803-2812.
25. Ison MG, Hui DS, Clezy K, et al. A clinical trial of intravenous peramivir compared with oral oseltamivir for the treatment of seasonal influenza in hospitalized adults. Antivir Ther 2013, 18:651-661.
26. Ison MG, Fraiz J, Heller B, et al. Intravenous peramivir for treatment of influenza in hospitalized patients. Antivir Ther 2013, published online Aug 28. http://dx.doi.org/10.3851/IMP2680.
27. BioCryst announces outcome from the peramivir phase 3 interim analysis, 7 Nov 2012 Business Wire, (accessed April 7, 2014). http://www.businesswire.com/news/home/20121107006831/en/BioCryst-Announces-Outcome-Peramivir-Phase-3-Interim#.U0I0-GfNu70.
28. Renaud C, Pergam SA, Polyak C, et al. Early emergence of an H275Y mutation in a hematopoietic cell transplant recipient treated with intravenous peramivir. Transpl Infect Dis 2010, 12:513-517.
29. Memoli MJ, Hrabal RJ, Hassantoufighi A, Eichelberger MC, Taubenberger JK Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts. Clin Infect Dis 2010, 50:1252-1255.
30. Yamashita M, Tomozawa T, Kakuta M, Tokumitsu A, Nasu H, Kubo S CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob Agents Chemother 2009, 53:186-192.
31. Chan-Tack KM, Gao A, Himaya AC, et al. Clinical experience with intravenous zanamivir under an emergency investigational new drug program in the United States. J Infect Dis 2013, 207:196-198.
32. Marty FM, Man CY, van der Horst C, et al. Safety and pharmacokinetics of intravenous zanamivir treatment in hospitalized adults with influenza: an open-label, multicenter, single-arm, phase II study. J Infect Dis 2014, 209:542-550.
33. Watanabe A, Chang SC, Kim MJ, Chu DW, Ohashi Y Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: a double-blind, randomized, noninferiority clinical trial. Clin Infect Dis 2010, 51:1167-1175. MARVEL study group.
34. Watanabe A A randomized double-blind controlled study of laninamivir compared with oseltamivir for the treatment of influenza in patients with chronic respiratory diseases. J Infect Chemother 2013, 19:89-97.
35. Marjuki H, Mishin VP, Chesnokov AP, et al. An investigational antiviral drug, DAS181, effectively inhibits replication of zoonotic influenza A virus subtype H7N9 and protects mice from lethality. J Infect Dis 2014, 210:435-440.
36. Moss RB, Hansen C, Sanders RL, Hawley S, Li T, Steigbigel RT A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection. J Infect Dis 2012, 206:1844-1851.
37. Chalkias S, Mackenzie MR, Gay C, et al. DAS181 treatment of hematopoietic stem cell transplant patients with parainfluenza virus lung disease requiring mechanical ventilation. Transpl Infect Dis 2014, 16:141-144.
38. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 2013, 100:446-454.
39. Tarbet EB, Maekawa M, Furuta Y, Babu YS, Morrey JD, Smee DF Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice. Antiviral Res 2012, 94:103-110.
40. Kobayashi O, Kashiwagi S, Iwamoto A, et al. Clinical effectiveness and safety of favipiravir, a novel anti-influenza drug with a selective inhibition activity against viral RNA polymerase. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, IL, USA; September 17, 2011.
41. Frech S, Epstein C. A Phase 2, randomized, double blind, placebo-controlled, multicenter study evaluating the safety and pharmacokinetics of different dosing regimens of favipiravir (T-705) in adult subjects with uncomplicated influenza, VIII Options for Control of Influenza; Cape Town, South Africa; September 5-10, 2013. Abstr O-905.
42. Rossignol JF, La Frazia S, Chiappa L, Ciucci A, Santoro MG Thiazolides. A new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level. J Biol Chem 2009, 284:29798-29808.
43. Romark announces clinical trial results for new influenza drug presented at IDSA meeting 2011 PR Newswire, (accessed April 7, 2014). http://www.prnewswire.com/news-releases/romark-announces-clinical-trial-results-for-new-influenza-drug-presented-at-idsa-meeting-2011-132309838.html.
44. Haffizulla J, Hartman A, Hoppers M, et al. Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial. Lancet Infect Dis 2014, 14:609-618.
45. Hui DS, Lee N, Chan PK Adjunctive therapies and immunomodulatory agents in the management of severe influenza. Antiviral Res 2013, 98:410-416.
46. Mair-Jenkins J, Saavedra-Campos M, Baillie K, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral aetiology: a systematic review and exploratory meta-analysis. J Infect Dis 2014, published online July 16. 10.1093/infdis/jiu396.
47. Hung IF, To KK, Lee CK, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 2011, 52:447-456.
48. Hung IF, To KK, Lee CK, et al. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest 2013, 144:464-473.
49. Nakamura G, Chai N, Park S, et al. An in vivo human-plasmablast enrichment technique allows rapid identification of therapeutic influenza A antibodies. Cell Host Microbe 2013, 14:93-103.
50. Dunning J, Baillie K, Cao B, Hayden FG. Antiviral combinations for severe influenza infections: a review. Lancet Infect Dis (in press).
51. Nguyen JT, Hoopes JD, Le MH, et al. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS One 2010, 5:e9332.
52. Duval X, van der Werf S, Blanchon T, et al. Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. PLoS Med 2010, 7:e1000362.
53. Kim WY, Young Suh G, Huh JW, et al. Triple-combination antiviral drug for pandemic H1N1 influenza virus infection in critically ill patients on mechanical ventilation. Antimicrob Agents Chemother 2011, 55:5703-5709.
54. Wang CH, Chung FT, Lin SM, et al. Adjuvant treatment with a mammalian target of rapamycin inhibitor, sirolimus, and steroids improves outcomes in patients with severe H1N1 pneumonia and acute respiratory failure. Crit Care Med 2014, 42:313-321.
55. Yan Y, Zou Z, Sun Y, et al. Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. Cell Res 2013, 23:300-302.
56. Vigerust DJ, McCullers JA Effectiveness of chloroquine against influenza. Influenza Other Respir Viruses 2008, 1:189-192.
57. Paton NI, Lee L, Xu Y, et al. Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial. Lancet Infect Dis 2011, 11:677-683.
58. Clinical decision-making support for treatment of MERS-CoV patients Public Health England, International Severe Acute Respiratory and Emerging Infections Consortium Treatment of MERS-CoV: information for cliniciansInternational Severe Acute Respiratory and Emerging Infections Consortium Treatment of MERS-CoV: information for clinicians, (accessed July 16, 2014). http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317139281416.
59. Hui DSC, Chan PKS Severe acute respiratory syndrome and coronavirus. Infect Dis Clin North Am 2010, 24:619-638.
60. Chan RW, Chan MC, Agnihothram S, et al. Tropism of and innate immune responses to the novel human betacoronavirus lineage C virus in human ex vivo respiratory organ cultures. J Virol 2013, 87:6604-6614.
61. Faure E, Poissy J, Goffard A, et al. Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside?. PLoS One 2014, 9:e88716.
62. Loutfy MR, Blatt LM, Siminovitch KA, et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA 2003, 290:3222-3228.
63. Falzarano D, de Wit E, Rasmussen AL, et al. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med 2013, 19:1313-1317.
64. Al-Tawfig J, Momattin H, Dib J, Memish ZA Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. Int J Infect Dis 2014, 20:42-46.
65. Arabi YM, Arifi AA, Balkhy HH, et al. Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection. Ann Intern Med 2014, 160:389-397.
66. Chan JF, Chan KH, Kao RY, et al. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J Infect 2013, 67:606-616.
67. Falzarano D, de Wit E, Martellaro C, et al. Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin. Sci Rep 2013, 3:1686.
68. Chan KS, Lai ST, Chu CM, et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicenter retrospective matched cohort study. Hong Kong Med J 2003, 9:399-406.
69. De Wilde AH, Raj VS, Oudshoorn D, et al. MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment. J Gen Virol 2013, 94:1749-1760.
70. Raj VS, Mou H Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013, 495:251-254.
71. Cheng Y, Wong R, Soo YO, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005, 24:44-46.
72. Buchholz U, Muller MA, Nitsche A, et al. Contact investigation of a case of human novel coronavirus infection treated in a German hospital, October-November 2012. Euro Surveill 2013, 18:20406.
73. Drosten C, Seilmaier M, Corman VM, et al. Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection. Lancet Infect Dis 2013, 13:745-751.
74. Lee N, Allen Chan KC, Hui DS, et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J Clin Virol 2004, 31:304-309.
75. Au Yeung TW, Lee JS, Lai WK, et al. The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study. J Infect 2005, 51:98-102.
76. Lat A, Bhadelia N, Miko B, et al. Invasive aspergillosis after pandemic (H1N1) 2009. Emerg Infect Dis 2010, 16:971-973.
77. Warn PA, Sharp A, Parmar A, Majithiya J, Denning DW, Hope WW Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect. Antimicrob Agents Chemother 2009, 53:3453-3461.
78. Seggewiss R, Einsele H Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update. Blood 2010, 115:3861-3868.
79. Leen AM, Myers GD, Sili U, et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 2006, 12:1160-1166.
80. Einsele H, Roosnek E, Rufer N, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002, 99:3916-3922.
81. Perruccio K, Tosti A, Burchielli E, et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood 2005, 106:4397-4406.
82. Feuchtinger T, Richard C, Joachim S, et al. Clinical grade generation of hexon-specific T cells for adoptive T-cell transfer as a treatment of adenovirus infection after allogeneic stem cell transplantation. J Immunother 2008, 31:199-206.
83. Uhlin M, Gertow J, Uzunel M, et al. Rapid salvage treatment with virus-specific T cells for therapy-resistant disease. Clin Infect Dis 2012, 55:1064-1073.
84. Hanley PJ, Shaffer DR, Cruz CR, et al. Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein-Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation. Cytotherapy 2011, 13:976-986.
85. Summerton J, Weller D Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Devel 1997, 7:187-195.
86. Aartsma-Rus A Antisense-mediated modulation of splicing: therapeutic implications for Duchenne muscular dystrophy. RNA Biol 2010, 7:453-461.
87. Ploegh HL Viral strategies of immune evasion. Science 1988, 280:248-253.
88. Pinto AK, Hill AB Viral interference with antigen presentation to CD8+ T cells: lessons from cytomegalovirus. Viral Immunol 2005, 18:434-444.
89. D'Orsogna LJ, van den Heuvel H, van der Meer-Prins EM, Roelen DL, Doxiadis II, Claas FH Stimulation of human EBV- and CMV-specific cytolytic effector function using allogeneic HLA molecules. J Immunol 2012, 189:4825-4831.
90. Macdonald WA, Chen Z, Gras S, et al. T cell allorecognition via molecular mimicry. Immunity 2009, 31:897-908.
91. Kochenderfer JN, Rosenberg SA Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol 2013, 10:267-276.
92. Henter J-I, Palmkvist-Kaijser K, Holzgraefe B, Bryceson YT, Palmér K Cytotoxic therapy for severe swine flu A/H1N1. Lancet 2010, 376:2116.
93. Jacobs MR, Koornhof HJ, Robins-Browne RM, et al. Emergence of multiply resistant pneumococci. N Engl J Med 1978, 299:735-740.
94. Marimon JM, Alonso M, Rolo D, Ardanuy C, Linares J, Perez-Trallero E Molecular characterization of Streptococcus pneumoniae invasive serotype 19A isolates from adults in two Spanish regions (1994-2009). Eur J Clin Microbiol Infect Dis 2012, 31:1009-1013.
95. Jenkins SG, Brown SD, Farrell DJ Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1-4. Ann Clin Microbiol Antimicrob 2008, 7:1.
96. Lynch JP, Zhanel GG Streptococcus pneumoniae: does antimicrobial resistance matter?. Semin Respir Crit Care Med 2009, 30:210-238.
97. Flamm RK, Sader HS, Farrell DJ, Jones RN Antimicrobial activity of ceftaroline tested against drug-resistant subsets of Streptococcus pneumoniae from US medical centers. Antimicrob Agents Chemother 2014, 58:2468-2471.
98. Drees M, Pineles L, Harris AD, Morgan DJ Variation in definitions and isolation procedures for multidrug-resistant gram-negative bacteria: a survey of the Society for Healthcare Epidemiology of America research network. Infect Control Hosp Epidemiol 2014, 35:362-366.
99. Antimicrobial resistance-global report and surveillance WHO, (accessed May 29, 2014). http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748_eng.pdf?ua=1.
100. Sader HS, Farrell DJ, Flamm RK, Jones RN Variation in potency and spectrum of tigecycline activity against bacterial strains from U.S. medical centers since its approval for clinical use (2006 to 2012). Antimicrob Agents Chemother 2014, 58:2274-2280.
101. Kattan JN, Villegas MV, Quinn JP New developments in carbapenems. Clin Microbiol Infect 2008, 14:1102-1111.
102. Jenkins SG, Fisher AC, Peterson JA, Nicholson SC, Kaniga K Meta-analysis of doripenem vs comparators in patients with pseudomonas infections enrolled in four phase III efficacy and safety clinical trials. Curr Med Res Opin 2009, 25:3029-3036.
103. Karageorgopoulos DE, Falagas ME Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis 2008, 8:751-762.
104. Landman D, Georgescu C, Martin DA, Quale J Polymyxins revisited. Clin Microbiol Rev 2008, 21:449-465.
105. Gales AC, Jones RN, Sader HS Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004). Clin Microbiol Infect 2006, 12:315-321.
106. Walkty A, DeCorby M, Nichol K, Karlowsky JA, Hoban DJ, Zhanel GG In vitro activity of colistin (polymyxin E) against 3,480 isolates of gram-negative bacilli obtained from patients in Canadian hospitals in the CANWARD study, 2007-2008. Antimicrob Agents Chemother 2009, 53:4924-4926.
107. Watkins RR, Papp-Wallace KM, Drawz SM, Bonomo RA Novel β-lactamase inhibitors: a therapeutic hope against the scourge of multidrug resistance. Front Microbiol 2013, 4:392.
108. Cetin ES, Tekeli A, Ozseven AG, Us E, Aridogan BC Determination of in vitro activities of polymyxin B and rifampin in combination with ampicillin/sulbactam or cefoperazone/sulbactam against multidrug-resistant Acinetobacter baumannii by the E-test and checkerboard methods. Jpn J Infect Dis 2013, 66:463-468.
109. Coates AR, Halls G Antibiotics in phase II and III clinical trials. Handb Exp Pharmacol 2012, 211:167-183.
110. Antibiotics currently in clinical development Antibiotics and Innovation Project, (accessed May 22, 2014). http://www.pewhealth.org/other-resource/antibiotics-currently-in-clinical-development-85899541594.
111. WHO global strategy for containment of antimicrobial resistance WHO, (accessed May 26, 2014). http://www.who.int/drugresistance/WHO_Global_Strategy_English.pdf?ua=1.
112. Hughes D, Karlén A Discovery and preclinical development of new antibiotics. Ups J Med Sci 2014, 119:162-169.
113. Global TB Report 2013 WHO, (accessed Jan 29, 2014). http://www.who.int/tb/publications/global_report/en/.
114. Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011, 38:516-528.
115. Zumla AI, Gillespie SH, Hoelscher M, et al. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. Lancet Infect Dis 2014, 14:327-340.
116. Zumla A, Nahid P, Cole ST Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov 2013, 12:388-404.
117. Lechartier B, Rybniker J, Zumla A, Cole S Tuberculosis drug discovery in the post-post-genomic era. EMBO Mol Med 2014, 6:158-166.
118. Centers for Disease Control and Prevention. MMWR Recomm Rep 2013, 62:1-12. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
119. Delamanid European Medicines Agency, (accessed May 28, 2014). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002552/WC500166235.pdf.
120. Zumla A, Maeurer M Rational development of adjunct immune-based therapies for drug-resistant tuberculosis: hypotheses and experimental designs. J Infect Dis 2012, 205(suppl 2):S335-S339.
121. Tobin DM, Roca FJ, Oh SF, et al. Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell 2012, 148:434-446.
122. Vilaplana C, Marzo E, Tapia G, Diaz J, Garcia V, Cardona PJ Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis. J Infect Dis 2013, 208:199-202.
123. Guzman JD, Evangelopoulos D, Gupta A, et al. Antitubercular specific activity of ibuprofen and the other 2-arylpropanoic acids using the HT-SPOTi whole-cell phenotypic assay. BMJ Open 2013, 3:e002672.
124. Gupta S, Cohen KA, Winglee K, Maiga M, Diarra B, Bishai WR Efflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2014, 58:574-576.
125. Gupta S, Tyagi S, Almeida DV, Maiga MC, Ammerman NC, Bishai WR Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor. Am J Respir Crit Care Med 2013, 188:600-607.
126. Maiga M, Ammerman NC, Maiga MC, et al. Adjuvant host-directed therapy with types 3 and 5 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatment. J Infect Dis 2013, 208:512-519.
127. Johnson BJ, Estrada I, Shen Z, et al. Differential gene expression in response to adjunctive recombinant human interleukin-2 immunotherapy in multidrug-resistant tuberculosis patients. Infect Immun 1998, 66:2426-2433.
128. Parida SK, Axelsson-Robertson R, Rao MV, et al. Totally drug-resistant tuberculosis and adjunct therapies. J Intern Med 2014, published online May 8. 10.1111/joim.12264.
129. Ianaro A, Ialenti A, Maffia P, et al. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther 2000, 292:156-163.
130. Skrahin A, Ahmed RK, Ferrara G, et al. Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial. Lancet Respir Med 2014, 2:108-122.
131. Brown GD, Denning DW, Gow NAR, Levitz S, Netea M, White T Human fungal infections: the hidden killers. Sci Transl Med 2012, 4:165rv13.
132. Nowaseb V, Gaebc E, Fraczek M, Richardson MD, Denning DW The frequency of Pneumocystis jirovecii in sputum samples of HIV and TB patients received at the Central Reference Laboratory in Windhoek, Namibia. J Infect Dev Ctries 2014, 8:349-357.
133. Denning D, Pleuvry A, Cole D Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis. Bull World Health Organ 2011, 89:864-872.
134. Denning DW, Bowyer P Voriconazole resistance in Aspergillus fumigatus-should we be concerned?. Clin Infect Dis 2013, 57:521-523.
135. Risk assessment on the impact of environmental usage of triazoles on the development and spread of resistance to medical triazoles in Aspergillus species European Centre for Disease Prevention and Control, (accessed May 24, 2014). http://www.ecdc.europa.eu/en/publications/publications/risk-assessment-impact-environmental-usage-of-triazoles-on-aspergillus-spp-resistance-to-medical-triazoles.pdf.
136. van der Linden JW, Snelders E, Kampinga GA, et al. Clinical implications of azole resistance in Aspergillus fumigatus, the Netherlands, 2007-2009. Emerg Infect Dis 2011, 17:1846-1854.
137. Howard SJ, Cerar D, Anderson MJ, et al. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 2009, 15:1068-1076.
138. Bueid A, Howard SJ, Moore CB, et al. Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009. J Antimicrob Chemother 2010, 65:2116-2118.
139. Denning DW, Park S, Lass-Florl C, et al. High frequency triazole resistance found in non-culturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin Infect Dis 2011, 52:1123-1129.
140. Denning DW, Pleuvry A, Cole DC Global burden of ABPA in adults with asthma and its complication chronic pulmonary aspergillosis. Med Mycol 2013, 51:361-370.
141. Denning DW Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy 2013, 43:850-873.
142. Mastella G, Rainisio M, Harms HK, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis. A European epidemiological study. Eur Resp J 2000, 16:464-471.
143. Baxter CG, Dunn G, Jones AM, et al. Novel immunologic classification of aspergillosis in adult cystic fibrosis. J Allergy Clin Immunol 2013, 132:560-566.
144. Burgel PR, Baixench MT, Amsellem M, et al. High prevalence of azole-resistant Aspergillus fumigatus in adults with cystic fibrosis exposed to itraconazole. Antimicrob Agents Chemother 2012, 56:869-874.
145. Kenyon C, Bonorchis K, Corcoran C, et al. A dimorphic fungus causing disseminated infection in South Africa. N Engl J Med 2013, 369:1416-1424.
146. Marr KA, Schlamm H, Rottinghaus ST, et al. A randomised, double-blind study of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis. 22nd European Congress of Clinical Microbiology and Infectious Diseases; London, UK March 31-April 2, 2012. Abstr LB2812.
147. Krishna G, Ma L, Martinho M, Preston RA, O'Mara E A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers. J Antimicrob Chemother 2012, 67:2725-2730.
148. Mølgaard-Nielsen D, Pasternak B, Hviid A Oral fluconazole during pregnancy and risk of birth defects. N Engl J Med 2013, 369:2061-2065. 21.
149. Denning DW, Hope WW Therapy for fungal diseases: opportunities and priorities. Trends Microbiol 2010, 18:195-204.
150. Van Rossem K, Lowe JA A Phase 1, randomized, open-label crossover study to evaluate the safety and pharmacokinetics of 400 mg albaconazole administered to healthy participants as a tablet formulation versus a capsule formulation. Clin Pharmacol 2013, 5:23-31.
151. Jiménez-Ortigosa C, Paderu P, Motyl MR, Perlin DS Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida species and Aspergillus species isolates. Antimicrob Agents Chemother 2014, 58:1248-1251.
152. Pfaller MA, Messer SA, Georgopapadakou N, Martell LA, Besterman JM, Diekema DJ Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens. J Clin Microbiol 2009, 47:3797-3804.
153. Shubitz LF, Trinh HT, Perrill RH, et al. Modeling nikkomycin Z dosing and pharmacology in murine pulmonary coccidioidomycosis preparatory to phase 2 clinical trials. J Infect Dis 2014, 209:1949-1954.
154. Mitsuyama J, Nomura N, Hashimoto K, et al. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine. Antimicrob Agents Chemother 2008, 52:1318-1324.
155. Advancing antifungal R&D F 2G, (accessed May 29, 2014). http://www.f2g.com/f2g-ltd-completes-30-million-financing-round-to-fund-pre-clinical-and-clinical-development-of-novel-anti-fungal-compounds/.
156. Zhai B, Wu C, Wang L, Sachs MS, Lin X The antidepressant sertraline provides a promising therapeutic option for neurotropic cryptococcal infections. Antimicrob Agents Chemother 2012, 56:3758-3766.
157. Bastidas RJ, Reedy JL, Morales-Johansson H, Heitman J, Cardenas ME Signaling cascades as drug targets in model and pathogenic fungi. Curr Opin Investig Drugs 2008, 9:856-864.
158. Veri A, Cowen LE Progress and prospects for targeting Hsp90 to treat fungal infections. Parasitology 2014, 20:1-11.
159. Raja Mohamed BS, Subramanian M, Shunmugiah KP Inhibition of Candida albicans virulence factors by novel levofloxacin derivatives. Appl Microbiol Biotechnol 2014, published online April 11. 10.1007/s00253-014-5719-2.
160. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992, 257:238-241.
161. Peggs KS, Verfuerth S, Pizzey A, et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 2003, 362:1375-1377.
162. Tramsen L, Schmidt S, Boenig H, et al. Clinical-scale generation of multi-specific anti-fungal T cells targeting Candida, Aspergillus and mucormycetes. Cytotherapy 2013, 15:344-351.
163. Dickson RP, Erb-Downward JR, Huffnagle GB Towards an ecology of the lung: new conceptual models of pulmonary microbiology and pneumonia pathogenesis. Lancet Respir Med 2014, 2:238-246.
164. Bates M, Mudenda V, Mwaba P, Zumla A Deaths due to respiratory tract infections in Africa: a review of autopsy studies. Curr Opin Pulmon Med 2013, 19:229-237.
165. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2095-2128.